Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

68.61 -0.22 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,590,052
Open 68.83
Bid (Size) 68.15 (20)
Ask (Size) 68.66 (4)
Prev. Close 68.83
Today's Range 68.06 - 69.00
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga

Performance

YTD
-17.58%
-17.58%
1 Month
+8.05%
+8.05%
3 Month
-5.86%
-5.86%
6 Month
-15.31%
-15.31%
1 Year
-9.74%
-9.74%

More News

Read More
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
7 Dividend Stocks to Buy Now: June 2024
Via InvestorPlace
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
MarketBeat Week in Review – 6/17 - 6/21
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Top Analyst Reports For Abbott, BP & Gilead
Via Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
Via Benzinga
Pre-Market Movers - June 21, 2024
Via Talk Markets
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Via MarketBeat
Exposures Product Safety
Defying the Norms: 3 High P/E Stocks With Room to Run
Via InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Via Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Via Benzinga
Topics Death
Exposures Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.